January 22, 2018 / 1:48 PM / a month ago

BRIEF-Sanofi CFO sees commercial, cost and tax synergies following Bioverativ deal

Jan 22 (Reuters) - Sanofi Chief financial officer Jerome Contamine says :

* sees commercial, cost and tax synergies related to the acquisition of U.S firm Bioverativ by France’s Sanofi Further company coverage: (Paris Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below